Accumulation of the Major Components from Polygoni Multiflori Radix in Liver and Kidney after Its Long-Term Oral Administrations in Rats

 

 Buy Article Permissions and Reprints

Abstract

Although Polygoni Multiflori Radix (PMR) has been widely used as a tonic and an anti-aging remedy for centuries, the extensively reported hepatotoxicity and potential kidney toxicity hindered its safe use in clinical practice. To better understand its toxicokinetics, the current study was proposed, aiming to evaluate the biodistributions of the major PMR components including 2,3,5,4′-tetrahydroxystilbene-2-O-β-D-glucopyranoside (TSG), emodin, emodin-8-O-β-D-glucopyranoside (EMG) and physcion as well as their corresponding glucuronides following bolus and multiple oral administrations of PMR to rats. Male Sprague-Dawley rats received a bolus dose or 21 days of oral administrations of PMR concentrated granules at 4.12 g/kg (equivalent to 20.6 g/kg raw material). Fifteen minutes after bolus dose or the last dose on day 21, rats were sacrificed and the blood, liver, and kidney were collected for the concentration determination of both parent form and glucuronides of TSG, emodin, EMG, and physcion by HPLC-MS/MS. Among all the tested analytes, TSG, EMG, EMG glucuronides in liver and TSG, EMG, as well as all the glucuronides of these analytes in the kidney demonstrated the most significant accumulation after multiple doses. Moreover, the levels of the parent analytes were all significantly higher in liver and kidney in comparison to their plasma levels. Strong tissue binding of all four analytes and accumulation of TSG, EMG, and EMG glucuronides in the liver and TSG, EMG, as well as the glucuronides of all four analytes in the kidney after multiple dosing of PMR were considered to be associated with its toxicity.

Publication History

Received: 01 April 2021

Accepted after revision: 02 August 2021

Article published online:
14 September 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• References

• 1 Lin LF, Ni BR, Lin HM, Zhang M, Li XC, Yin XB, Qu CH, Ni J. Traditional usages, botany, phytochemistry, pharmacology and toxicology of Polygonum multiflorum Thunb.: A review. J Ethnopharmacol 2015; 159: 158-183
  CrossrefPubMedGoogle Scholar
• 2 Commission TCP. Chinese Pharmacopoeia. Beijing, China: China Medical Science Press; 2015: 175-177
  Google Scholar
• 3 But PP, Tomlinson B, Lee K. Hepatitis related to the Chinese medicine Shou-wu-pian manufactured from Polygonum multiflorum . Vet Human Toxicol 1996; 38: 280-282
  PubMedGoogle Scholar
• 4 Park GJH, Mann SP, Ngu MC. Acute hepatitis induced by Shou-Wu-Pian, a herbal product derived from Polygonum multiflorum . J Gastroenterol Hepatol 2001; 16: 115-117
  CrossrefPubMedGoogle Scholar
• 5 Cárdenas A, Restrepo JC, Sierra F, Correa G. Acute hepatitis due to shen-min: A herbal product derived from Polygonum multiflorum . J Clin Gastroenterol 2006; 40: 629-632
  CrossrefPubMedGoogle Scholar
• 6 Laird AR, Ramchandani N, deGoma EM, Avula B, Khan IA, Gesundheit N. Acute hepatitis associated with the use of an herbal supplement (Polygonum multiflorum) mimicking iron-overload syndrome. J Clin Gastroenterol 2008; 42: 861-862
  CrossrefPubMedGoogle Scholar
• 7 Cho HC, Min HJ, Ha CY, Kim HJ, Kim TH, Jung WT, Lee OJ, Bae IG. Reactivation of pulmonary tuberculosis in a patient with Polygonum multiflorum Thunb-induced hepatitis. Gut Liver 2009; 3: 52
  CrossrefPubMedGoogle Scholar
• 8 Jung KA, Min HJ, Yoo SS, Kim HJ, Choi SN, Ha CY, Kim HJ, Kim TH, Jung WT, Lee OJ. Drug-induced liver injury: Twenty five cases of acute hepatitis following ingestion of Polygonum multiflorum thunb. Gut Liver 2011; 5: 493
  CrossrefPubMedGoogle Scholar
• 9 Dong H, Slain D, Cheng J, Ma W, Liang W. Eighteen cases of liver injury following ingestion of Polygonum multiflorum . Complement Ther Med 2014; 22: 70-74
  CrossrefPubMedGoogle Scholar
• 10 Program NT. NTP Toxicology and Carcinogenesis Studies of EMODIN (CAS NO. 518-82-1) Feed Studies in F344/N Rats and B6C3F1 Mice. Natl Toxicol Program Tech Rep Ser 2001; 493: 1-278
  PubMedGoogle Scholar
• 11 Gong X, Liu M, Gong L, Li Y, Peng C. Study on hepatotoxicity of different dosages of Polygoni multiflori radix praeparata in rats by metabolomics based on UPLC-Q-TOF-MS. J Pharm Biomed Anal 2019; 175: 112760
  CrossrefPubMedGoogle Scholar
• 12 Wang L, Sang M, Liu E, Banahene PO, Zhang Y, Wang T, Han L, Gao X. Rapid profiling and pharmacokinetic studies of major compounds in crude extract from Polygonum multiflorum by UHPLC-Q-TOF-MS and UPLC-MS/MS. J Pharm Biomed Anal 2017; 140: 45-61
  CrossrefPubMedGoogle Scholar
• 13 Yao S, Li Y, Kong L. Preparative isolation and purification of chemical constituents from the root of Polygonum multiflorum by high-speed counter-current chromatography. J Chromatogr A 2006; 1115: 64-71
  CrossrefPubMedGoogle Scholar
• 14 Zhang L, Ma WF, Li J, He J, Zhang P, Zheng F, Zhang BL, Gao X, Chang Y. Influence of processing on pharmacokinetic of typical constituents in radix polygoni multiflori after oral administration by LC-ESI-MS/MS. J Ethnopharmacol 2013; 148: 246-253
  CrossrefPubMedGoogle Scholar
• 15 Lin LF, Ni BR, Lin HM, Cao S, Yang C, Zhao Y, Xue D, Ni J. Simultaneous determination and pharmacokinetic study of P-hydroxybenzaldehyde, 2,3,5,4′-tetrahydroxystilbene-2-O-β-glucoside, emodin-8-O-β-d-glucopyranoside, and emodin in rat plasma by liquid chromatography tandem mass spectrometry after oral administration of Polygonum multiflorum . Anal Methods 2015; 7: 244-252
  CrossrefPubMedGoogle Scholar
• 16 Zhang M, Lin LF, Lin HM, Qu C, Yan L, Ni J. Interpretation the hepatotoxicity based on pharmacokinetics investigated through oral administrated different extraction parts of Polygonum multiflorum on rats. Front Pharmacol 2018; 9: 505
  CrossrefPubMedGoogle Scholar
• 17 Cheng WH, Li YH, Yang W, Wu S, Wei M, Gao Y, Kang C, Zhang S, Li Y. Simultaneous determination of 13 constituents of Radix Polygoni Multiflori in rat plasma and its application in a pharmacokinetic study. Int J Anal Chem 2020; 2020: 1-10
  CrossrefPubMedGoogle Scholar
• 18 Lin L, Lin H, Zhang M, Ni B, Yin X, Qu C, Ni J. A novel method to analyze hepatotoxic components in Polygonum multiflorum using ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry. J Hazard Mater 2015; 299: 245-259
  PubMedGoogle Scholar
• 19 Kang L, Si L, Rao J, Li D, Wu Y, Wu SL, Wu MH, He SJ, Zhu WW, Wu Y, Xu JQ, Li G, Huang JG. Polygoni Multiflori Radix derived anthraquinones alter bile acid disposition in sandwich-cultured rat hepatocytes. Toxicol In Vitro 2017; 40: 313-323
  CrossrefPubMedGoogle Scholar
• 20 Jing XB, Ueki N, Cheng JD, Imanishi H, Hada T. Induction of apoptosis in hepatocellular carcinoma cell lines by emodin. Jpn J Cancer Res 2002; 93: 874-882
  CrossrefPubMedGoogle Scholar
• 21 Shieh DE, Chen YY, Yen MH, Chiang LC, Lin CC. Emodin-induced apoptosis through p53-dependent pathway in human hepatoma cells. Life Sc 2004; 74: 2279-2290
  CrossrefPubMedGoogle Scholar
• 22 Subramaniam A, Shanmugam MK, Ong TH, Li F, Perumal E, Chen LX, Vali S, Abbasi T, Kapoor S, Ahn KS, Kumar AP, Hui KM, Sethi G. Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3. Br J Pharmacol 2013′ 170: 807 – 821.
  PubMedGoogle Scholar
• 23 Yu JQ, Bao W, Lei JC. Emodin regulates apoptotic pathway in human liver cancer cells. Phytother Res 2013; 27: 251-257
  CrossrefPubMedGoogle Scholar
• 24 Cui YT, Lu PR, Song G, Liu Q, Zhu D, Liu XB. Involvement of PI3K/Akt, ERK and p38 signaling pathways in emodin-mediated extrinsic and intrinsic human hepatoblastoma cell apoptosis. Food Chem Toxicol 2016; 92: 26-37
  CrossrefPubMedGoogle Scholar
• 25 Dong XX, Ni BR, Fu NJ, Yin XB, You LT, Leng X, Liang X, Ni J. Emodin induces apoptosis in human hepatocellular carcinoma HepaRG cells via the mitochondrial caspase-dependent pathway. Oncol Rep 2018; 40: 1985-1993
  PubMedGoogle Scholar
• 26 Zheng XY, Yang SM, Zhang R, Wang SM, Li GB, Zhou SW. Emodin-induced autophagy against cell apoptosis through the PI3K/AKT/mTOR pathway in human hepatocytes. Drug Des Dev Ther 2019; 13: 3171
  CrossrefPubMedGoogle Scholar
• 27 Zhang L, Liu XY, Tu C, Li CY, Song D, Zhu JX, Zhou YY, Wang XH, Li RS, Xiao XH, Liu YP, Wang JB. Component synergy between stilbenes and emodin derivatives contributes to hepatotoxicity induced by Polygonum multiflorum . Xenobiotica 2020; 50: 515-525
  CrossrefPubMedGoogle Scholar
• 28 Yang JB, Gao HY, Song YF, Liu Y, Wang Q, Wang Y, Ma SC, Chang XL, Wei F. Advances in understanding the metabolites and metabolomics of Polygonum multiflorum Thunb: a mini review. Curr Drug Metab 2021; 22: 165-172
  PubMedGoogle Scholar
• 29 Dong Q, Li N, Li Q, Zhang CE, Feng WW, Li GQ, Li RY, Tu C, Han X, Bai ZF, Zhang YM, Niu M, Ma ZJ, Xiao XH, Wang JB. Screening for biomarkers of liver injury induced by Polygonum multiflorum: targeted metabolomic study. Front Pharmacol 2015; 6: 217
  CrossrefPubMedGoogle Scholar
• 30 Zhang Y, Wang N, Zhang M, Diao T, Tang J, Dai M, Chen S, Lin G. Metabonomics study on Polygonum multiflorum induced liver toxicity in rats by GC-MS. Int J Clin Exp Med 2015; 8: 10986-10992
  PubMedGoogle Scholar
• 31 Xia XH, Yuan YY, Liu M. The assessment of the chronic hepatotoxicity induced by Polygoni multiflori Radix in rats: a pilot study by using untargeted metabolomics method. J Ethnopharmacol 2017; 203: 182-190
  CrossrefPubMedGoogle Scholar
• 32 Zhang L, Niu M, Wei AW, Tang JF, Tu C, Bai ZF, Zou ZS, Xiao XH, Liu YP, Wang JB. Risk profiling using metabolomic characteristics for susceptible individuals of drug-induced liver injury caused by Polygonum multiflorum . Arch Toxicol 2020; 94: 245-256
  CrossrefPubMedGoogle Scholar
• 33 Yan Y, Shi N, Han X, Li G, Wen B, Gao J. UPLC/MS/MS-based metabolomics study of the hepatotoxicity and nephrotoxicity in rats induced by Polygonum multiflorum Thunb. ACS Omega 2020; 5: 10489-10500
  CrossrefPubMedGoogle Scholar
• 34 Hong Kong Chinese Materia Medica Standards, Volume 2. Accessed February 1, 2021 at: http://www.cmd.gov.hk/hkcmms/vol2/main.html
  PubMed
• 35 US Food and Drug Administration. Guidance for Industry, Bioanalytical Method Validation. Rockville, MD: Center for Drug Evaluation and Research; 2018
  Google Scholar
• 36 US Food and Drug Administration. International Conference on Harmonization (ICH), Q2 (R1) Validation of Analytical Procedures: Text and Methodology. Rockville, MD: Center for Drug Evaluation and Research; 2005
  Google Scholar
• 37 Ma J, Zheng L, He YS, Li HJ. Hepatotoxic assessment of Polygoni Multiflori radix extract and toxicokinetic study of stilbene glucoside and anthraquinones in rats. J Ethnopharmacol 2015; 162: 61-68
  CrossrefPubMedGoogle Scholar
• 38 Liu Y, Wang W, Sun M, Ma B, Pang L, Du Y, Dong X, Yin X, Ni J. Polygonum multiflorum-induced liver injury: clinical characteristics, risk factors, material basis, action mechanism and current challenges. Front Pharmacol 2019; 10: 1467
  CrossrefPubMedGoogle Scholar
• 39 Li D, Yang MB, Zuo Z. Overview of pharmacokinetics and liver toxicities of radix Polygoni Multiflori. Toxins (Basel) 2020; 12: 729
  CrossrefPubMedGoogle Scholar
• 40 Shia CS, Tsai SY, Lin JC, Li ML, Ko MH, Chao PD, Huang YC, Hou YC. Steady-state pharmacokinetics and tissue distribution of anthraquinones of Rhei Rhizoma in rats. J Ethnopharmacol 2011; 137: 1388-1394
  CrossrefPubMedGoogle Scholar
• 41 Lin SP, Chu PM, Tsai SY, Wu MH, Hou YC. Pharmacokinetics and tissue distribution of resveratrol, emodin and their metabolites after intake of Polygonum cuspidatum in rats. J Ethnopharmacol 2012; 144: 671-676
  CrossrefPubMedGoogle Scholar
• 42 Lv G, Lou Z, Chen S, Gu H, Shan L. Pharmacokinetics and tissue distribution of 2,3,5,4′-tetrahydroxystilbene-2-O-beta-D-glucoside from traditional Chinese medicine Polygonum multiflorum following oral administration to rats. J Ethnopharmacol 2011; 137: 449-456
  CrossrefPubMedGoogle Scholar
• 43 Peng J, Song ZF, Ma C. Emodin Studies on Pharmacokinetics and Distribution in Rat Liver after Polygonum cuspidatum Sieb. et Zucc. Extract Administration. Mode Tradit Chin Med Mater Med 2008; 10: 64-67
  PubMedGoogle Scholar
• 44 Shi YB, Li JC, Ren Y, Wang H, Cong Z, Wu G, Du L, Li H, Zhang X. Pharmacokinetics and tissue distribution of emodin loaded nanoemulsion in rats. J Drug Deliv Sci Technol 2015; 30: 242-249
  CrossrefPubMedGoogle Scholar
• 45 Zhao Y, Zhang L, Feng Y, Chen DQ, Xi ZH, Du X, Bai X, Lin RC. Pharmacokinetics of 2,3,5,4′-tetrahydroxystilbene-2-O-beta-D-glucoside in rat using ultra-performance LC-quadrupole TOF-MS. J Sep Sci 2013; 36: 863-871
  CrossrefPubMedGoogle Scholar
• 46 Wang WJ, Liu DL, Wang W. The stability study of stilbene glucoside and its β-cyclodextrin inclusion complex. Global Traditional Chinese Medicine 2016; 9: 414-418
  PubMedGoogle Scholar
• 47 Li Y. Studies on the stability of stilbene glycoside. Fujian Med J 2011; 33: 58-60
  PubMedGoogle Scholar
• 48 Tamura M, Koshibe Y, Kaji K, Ueda J, Shirataki Y. Attempt to Synthesize 2,3,5,4′-Tetrahydroxystilbene Derived from 2,3,5,4′-Tetrahydroxystilbene-2-O-β-Glucoside (THSG). Chem Pharm Bull 2015; 63: 122-125
  CrossrefPubMedGoogle Scholar
• 49 Fu JF, Wu SY, Wang M, Tian Y, Zhang JJ, Song R. Intestinal metabolism of Polygonum cuspidatum in vitro and in vivo . Biomedical Chromatograph 2018; 32: e4190
  CrossrefPubMedGoogle Scholar
• 50 Sun Y, Wang YX, Chen QH. Absorption, distribution and excretion of physcion in rat. J China Pharm Univ 1988; 19: 179-181
  PubMedGoogle Scholar

• Supplementary Material